Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting>
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …

As we age, we experience changes in our nighttime sleep and daytime wakefulness.
Individuals afflicted with Alzheimer's disease (AD) can develop sleep problems even before …

Abstract Background Dementia with Lewy bodies (DLB) and Parkinson's disease dementia
(PDD), which share many clinical, neurochemical, and morphological features, have been …

Importance There is increasing evidence that Parkinson disease (PD) is heterogeneous in
its clinical presentation and prognosis. Defining subtypes of PD is needed to better …

Dementia with Lewy bodies (DLB) and Parkinson's disease-dementia (PDD), although
sharing many clinical, neurochemical and morphological features, according to DSM-5, are …

Sleep disorders are among the most common non-motor manifestations in Parkinson's
disease (PD) and have a significant negative impact on quality of life. While sleep disorders …

Objective: To precisely delineate clinical risk factors for conversion from idiopathic REM
sleep behavior disorder (RBD) to Parkinson disease, dementia with Lewy bodies, and …

Increasing recognition that Parkinson's disease (PD) may start outside of the substantia
nigra has led to a rapidly expanding effort to define prodromal stages of PD, before motor …

Objective: To establish the diagnostic accuracy of the Montreal Cognitive Assessment
(MoCA) when screening externally validated cognition in Parkinson disease (PD), by …

Abstract The Montreal Cognitive Assessment (MoCA) is a cognitive screening instrument
developed to detect mild cognitive impairment (MCI). It is a simple 10 min paper and pencil …